What happens when oxalate nephropathy & renal embolic disease interact? How does this interaction impact kidney function? Find out the answer in our latest #Collidescope episode!

#renalpath #kidneypath #pathsky #renalsky

In this week's #Collidescope case, Dr. Charles investigates a case of oxalate nephropathy & renal embolic disease. Watch the episode to learn more about how these two diseases interact and affect kidney function. 

#renalpath #kidneypath #pathsky #renalsky

What happens when oxalate nephropathy & renal embolic disease interact? How does this interaction impact kidney function? Find out the answer in our latest #Collidescope episode!

#renalpath #kidneypath #pathsky #renalsky

📕 New in the Society of Toxicology journal Toxicological Sciences, "Chronic exposure to low levels of glyphosate and metals induces kidney dysfunction" with Iain Drummond & team.

🧪 🐟🎸 #ScientificResearchPublishing #NephSky #RenalSky

https://doi.org/10.1093/toxsci/kfag007

Dr. Charles is back with another #Collidescope case! Learn about how oxalate & renal embolic disease interact and affect kidney function! #renalpath #kidneypath #pathsky #renalsky

By studying tiny African turquoise killifish that show classic signs of aging in just months, researchers are unlocking how SGLT2 inhibitors help maintain tissue health far beyond what we understood before. 🧪 🐟🎸 #NephSky #RenalSky

https://ow.ly/eWW150XVPXk

1/ This is a case of collapsing glomerulopathy, which is most commonly seen in African Americans in association with APOL1 high risk alleles.

#renalpath #kidneypath #pathology #renalsky #pathsky

(1/2) A case of IgA nephropathy but in a limited sample. Cortex was present for immunofluorescence microscopy so, a diagnosis could be made. 

#renalpathology #renalsky #GlomGoals #biopsyadequacy

Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of...

Published in @thelancet.com

Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits www.thelancet.com/journals/lan... #GLP-1

#MedSky #EndoSky #CardioSky #RenalSky

Have you caught up on our latest collision case? Learn more about what happens when two diseases collide in one case and how kidney function is affected. #kidneypath #renalsky #pathsky #Collidescope

Check out the episode here: 

(1/2) A case of IgA nephropathy but in a limited sample. Cortex was present for immunofluorescence microscopy so, a diagnosis could be made. 

#GlomGoals #bxadequacy #renalpathology #renalsky

A dual case of crescentic glomerulonephritis and thrombotic microangiopathy (secondary to gemcitabine) in a patient with metastatic lung cancer, AKI, hematuria and proteinuria. 

#UnderTheScope #renalpath #pathsky #renalsky

📚 New paper published in Kidney International, "Sodium-glucose co-transporter 2 inhibition improves age-dependent kidney microvascular rarefaction" by Anastasia Paulmann, Hermann Haller & team: https://doi.org/10.1016/j.kint.2025.12.011

#NephSky #RenalSky #ScientificResearchPublishing 🧪 👩‍🔬

This seminar will feature the latest research from Dr. Sears' laboratory on the role of renal adaptations in response to exercise training. #renalsky @uoflenvirome.bsky.social @uoflmedicine.bsky.social @stevenpjones.bsky.social

Empagliflozin in chronic kidney disease: evidence for early, inclusive, and confident use The scenario of chronic kidney disease (CKD) management has been transformed by the advent of sodium glucose co-transporter-2 (SGLT2) inhibitors, a class of drugs with benefits extending well beyond g...

Linked Comment:
Empagliflozin in chronic kidney disease: evidence for early, inclusive, and confident use www.thelancet.com/journals/lan...
#CKD

#MedSky #EndoSky #RenalSky

Empagliflozin in chronic kidney disease: evidence for early, inclusive, and confident use The scenario of chronic kidney disease (CKD) management has been transformed by the advent of sodium glucose co-transporter-2 (SGLT2) inhibitors, a class of drugs with benefits extending well beyond g...

Also read the Linked Comment;
#Empagliflozin in chronic #kidney disease: evidence for early, inclusive, and confident use www.thelancet.com/journals/lan...
#CKD #T2D
#FREE to read with registration (also FREE)

#MedSky #endoSky #RenalSky

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis SGLT2 inhibition reduces risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR. Kidney benefits are evident irrespective of diabetes status, heart failure status,...

#SGLT2 inhibition reduces risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR www.thelancet.com/journals/lan...
#CKD #T2D
#OpenAccess

#MedSky #EndoSky #RenalSky

Read our December Issue, featuring familial hypercholesterolaemia, chronic kidney disease, type 2 diabetes, cyclic Cushing’s syndrome, primary aldosteronism, type 1 diabetes, menopause, obesity, iodine deficiency, & much more tinyurl.com/mwfu4c6m

#MedSky #EndoSky #RenalSky #CardioSky

Collaboration fuels discovery — and #KidneyWk is where it happens!

MDI Bio Lab is proud to join the world’s leading nephrology researchers this week in Houston at the annual ASNKidney conference. Will they see you there?

#researchmatters 🧪 🤝 🐟🎸 🍎 👩‍🔬 🌎 🖥️ 🧬 #NephSky #RenalSky

Sharing with #Nephsky #renalsky #ruralhealth

Empagliflozin in chronic kidney disease: evidence for early, inclusive, and confident use The scenario of chronic kidney disease (CKD) management has been transformed by the advent of sodium glucose co-transporter-2 (SGLT2) inhibitors, a class of drugs with benefits extending well beyond g...

Linked Comment:
#Empagliflozin in chronic #kidney disease: evidence for early, inclusive, and confident use www.thelancet.com/journals/lan...
#SGLT2 inhibitor #CKD
#FREE to read with registration (also FREE)

#MedSky #EndoSky #RenalSky

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis SGLT2 inhibition reduces risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR. Kidney benefits are evident irrespective of diabetes status, heart failure status,...

#SGLT2 inhibition reduces risk of acute and chronic #kidney outcomes irrespective of the size of the acute dip in eGFR www.thelancet.com/journals/lan... #CKD
#OpenAccess

#MedSky #EndoSky #RenalSky

Empagliflozin in chronic kidney disease: evidence for early, inclusive, and confident use The scenario of chronic kidney disease (CKD) management has been transformed by the advent of sodium glucose co-transporter-2 (SGLT2) inhibitors, a class of drugs with benefits extending well beyond g...

Carmine Zoccali & Francesca Mallamaci comment on:
#Empagliflozin in chronic #kidney disease: evidence for early, inclusive, and confident use thelancet.com/journals/lan...
#SGLT2 inhibitor #CKD
#FREE to read with registration (also FREE)

#MedSky #EndoSky #RenalSky

Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis SGLT2 inhibition reduces risk of acute and chronic kidney outcomes irrespective of the size of the acute dip in eGFR. Kidney benefits are evident irrespective of diabetes status, heart failure status,...

New—Effects of #empagliflozin on conventional and exploratory acute and chronic #kidney outcomes: an individual participant-level meta-analysis thelancet.com/journals/lan...
#SGLT2 inhibitor #CKD
#OpenAccess

#MedSky #EndoSky #RenalSky

Revisiting proliferative glomerulonephritis with monoclonal immunoglobulin deposits through immunoglobulin repertoire sequencing

doi.org/10.1016/j.kint.2025.07.039

#NephSky #MedSky #kidneypath #renalsky @mayoclinic.org

Glom Goals: Why Adequacy Matters Glom Goals · Episode

Thank you to @nephrowhitt.bsky.social, @juancarlosqvelez.bsky.social, and Dr. Vandana Niyyar for joining @nephrosharma.bsky.social, @glombandit.bsky.social, for this vital conversation.

#nephsky #renalsky #kidneypath

How did the frequency of inadequate renal biopsies go from <1% in 2004 up to 27% in 2025?

Listen to our podcast for more insight on this crisis: youtu.be/GSUhu9ysNyM?...

#renal #kidneypath #nephsky #renalsky #nephrology

Here is today’s #eyeSCANdy! Portions of glomerular tuft with collapsed GBM (across top), spicular amyloid (middle right), and nodular amyloid (middle left).

Photo courtesy of Dr. Stephen Bonsib. #renal #pathology #kidneypath #pathsky #renalsky

LISTEN TO THE PODCAST HERE: youtu.be/GSUhu9ysNyM?...

#GLOMGOALS #renalsky #pathsky #kidneypath #nephrology #kidneybiopsy #biopsyadequacy

What exactly is an inadequate renal biopsy? Why are 27% of biopsies inadequate? What can be done to fix this?

Check the thread to listen to @nephrosharma.bsky.social, @glombandit.bsky.social, @nephrowhitt.bsky.social, and @juancarlosqvelez.bsky.social discuss this challenge. #RenalPath #RenalSky